ACADIA Pharmaceuticals Inc. DR6.F Stock
ACADIA Pharmaceuticals Inc. Price Chart
ACADIA Pharmaceuticals Inc. DR6.F Financial and Trading Overview
ACADIA Pharmaceuticals Inc. stock price | 13.81 EUR |
Previous Close | 22 EUR |
Open | 22 EUR |
Bid | 22 EUR x 30000 |
Ask | 22.6 EUR x 30000 |
Day's Range | 22 - 22 EUR |
52 Week Range | 13.23 - 23.8 EUR |
Volume | 50 EUR |
Avg. Volume | 28 EUR |
Market Cap | 3.62B EUR |
Beta (5Y Monthly) | 0.525352 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 25.53 EUR |
DR6.F Valuation Measures
Enterprise Value | 3.33B EUR |
Trailing P/E | N/A |
Forward P/E | -23.913044 |
PEG Ratio (5 yr expected) | -0.57 |
Price/Sales (ttm) | 6.9541416 |
Price/Book (mrq) | 9.544468 |
Enterprise Value/Revenue | 6.407 |
Enterprise Value/EBITDA | -20.546 |
Trading Information
ACADIA Pharmaceuticals Inc. Stock Price History
Beta (5Y Monthly) | 0.525352 |
52-Week Change | 22.33% |
S&P500 52-Week Change | 20.43% |
52 Week High | 23.8 EUR |
52 Week Low | 13.23 EUR |
50-Day Moving Average | 19.51 EUR |
200-Day Moving Average | 17.23 EUR |
DR6.F Share Statistics
Avg. Volume (3 month) | 28 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 162.62M |
Float | 110.72M |
Short Ratio | N/A |
% Held by Insiders | 0.22% |
% Held by Institutions | 97.70% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -28.053% |
Operating Margin (ttm) | -31.55% |
Gross Margin | 29.07% |
EBITDA Margin | -31.18% |
Management Effectiveness
Return on Assets (ttm) | -16.037% |
Return on Equity (ttm) | -35.63% |
Income Statement
Revenue (ttm) | 520.23M EUR |
Revenue Per Share (ttm) | 3.21 EUR |
Quarterly Revenue Growth (yoy) | 2.60% |
Gross Profit (ttm) | 145.49M EUR |
EBITDA | -162228000 EUR |
Net Income Avi to Common (ttm) | -145940000 EUR |
Diluted EPS (ttm) | -0.84 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 402.87M EUR |
Total Cash Per Share (mrq) | 2.48 EUR |
Total Debt (mrq) | 60.61M EUR |
Total Debt/Equity (mrq) | 16.2 EUR |
Current Ratio (mrq) | 2.242 |
Book Value Per Share (mrq) | 2.305 |
Cash Flow Statement
Operating Cash Flow (ttm) | -55639000 EUR |
Levered Free Cash Flow (ttm) | 68.01M EUR |
Profile of ACADIA Pharmaceuticals Inc.
Country | Germany |
State | CA |
City | San Diego |
Address | 12830 El Camino Real |
ZIP | 92130 |
Phone | 858 558 2871 |
Website | https://acadia.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 540 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
Q&A For ACADIA Pharmaceuticals Inc. Stock
What is a current DR6.F stock price?
ACADIA Pharmaceuticals Inc. DR6.F stock price today per share is 13.81 EUR.
How to purchase ACADIA Pharmaceuticals Inc. stock?
You can buy DR6.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ACADIA Pharmaceuticals Inc.?
The stock symbol or ticker of ACADIA Pharmaceuticals Inc. is DR6.F.
Which industry does the ACADIA Pharmaceuticals Inc. company belong to?
The ACADIA Pharmaceuticals Inc. industry is Biotechnology.
How many shares does ACADIA Pharmaceuticals Inc. have in circulation?
The max supply of ACADIA Pharmaceuticals Inc. shares is 165.22M.
What is ACADIA Pharmaceuticals Inc. Price to Earnings Ratio (PE Ratio)?
ACADIA Pharmaceuticals Inc. PE Ratio is now.
What was ACADIA Pharmaceuticals Inc. earnings per share over the trailing 12 months (TTM)?
ACADIA Pharmaceuticals Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the ACADIA Pharmaceuticals Inc. company belong to?
The ACADIA Pharmaceuticals Inc. sector is Healthcare.